NKGen Biotech, Inc., a clinical-stage biotechnology company, develops cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells. Its lead products include SNK01, an autologous NK cell therapy candidate for the treatment of neurodegenerative diseases, and SNK02, an allogeneic NK cell therapy for refractory solid tumors. The company has a license agreement with NKMAX for its NK cell program. The company has a strategic partnership with HekaBio K.K. for the development of the company's autologous NK cell therapy, troculeucel, in Japan. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California. Show more

Location: 3001 Daimler Street, Santa Ana, CA, 92705, United States | Website: https://nkgenbiotech.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

10.93M

52 Wk Range

$0.10 - $0.96

Previous Close

$0.10

Open

$0.00

Volume

500

Day Range

$0.00 - $0.10

Enterprise Value

41.66M

Cash

8.00K

Avg Qtr Burn

-5.217M

Insider Ownership

55.28%

Institutional Own.

0.00%

Qtr Updated

09/30/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Troculeucel (SNK01) Details Alzheimer's disease	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SNK01 Details Parkinson's disease, Neurodegenerative disease	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SNK02 Details Solid tumor/s, Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Troculeucel (SNK01) Details no known indication	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.